Blackford and See-Mode Partner to Bring AI Breast and
EDINBURGH, Scotland, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Blackford, the pioneering strategic AI platform and solutions provider, and See-Mode today ...
Read moreEDINBURGH, Scotland, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Blackford, the pioneering strategic AI platform and solutions provider, and See-Mode today ...
Read moreKAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes ...
Read moreELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with ...
Read moreThis new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of ...
Read moreNew data presented at the San Antonio Breast Cancer Symposium demonstrates strong detection performance of stage I breast cancer and ...
Read moreExperts from across Latin America explore how to improve access to recommended treatment practices based on the latest international guidelines. ...
Read more- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.